11
LIU BINGCAN: Analogues for the treatment or prevention of flavivirus infections. VERTEX PHARMACEUTICALS INCORPORATED, Davis Steven G, June 30, 2011: WO/2011/079327 (30 worldwide citation)

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4, R4', R5, R5'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.


12
HENDERSON JAMES A: Benzimidazole analogues for the treatment or prevention of flavivirus infections. VERTEX PHARMACEUTICALS INCORPORATED, Davis Steven G, January 20, 2011: WO/2011/009084 (30 worldwide citation)

Compounds represented by formula (I) or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R1, R1 ', R2, R2', R3, R3', R5, R5', R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.


13
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Ye Yuanjie, Singh Suresh B, Himmelsbach Frank: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Ye Yuanjie, Singh Suresh B, Himmelsbach Frank, DAVIS Steven G, November 5, 2009: WO/2009/134387 (29 worldwide citation)

This invention relates to novel compounds of the Formula I1 Ik, Im3, Im4, Im6-12, In3, In4, In6-12, lo3, lo4, lo6-12, Ip2, Ip4-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulat ...


14
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Ye Yuanjie, Singh Suresh B: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Ye Yuanjie, Singh Suresh B, DAVIS Steven G, November 5, 2009: WO/2009/134384 (28 worldwide citation)

This invention relates to novel compounds of the Formula (I), (II), lu1-20, Iv1-20, Iw1-20, Ix1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 1 β-HSD1 i ...


15
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias, DAVIS Steven G, November 5, 2009: WO/2009/134392 (28 worldwide citation)

This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in m ...


16
Xu Zhenrong: Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Vitae Pharmaceuticals, Xu Zhenrong, DAVIS Steven G, February 5, 2009: WO/2009/017671 (27 worldwide citation)

Disclosed are syntheses of 11 β-HSDl inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascul ...


17
Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei: Cyclic urea inhibitors of 11β -hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei, DAVIS Steven G, May 14, 2009: WO/2009/061498 (27 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih)1 (Ij), (Ik), (II1-3). (Im1-3), (In1-3), (lo1-2), (Ip1-6), (Iq1-6), (Ir1-6) and (Is1-2), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful fo ...


18
DILLARD LAWRENCE W: Inhibitors of beta-secretase. DILLARD LAWRENCE W, Davis Steven G, September 1, 2011: WO/2011/106414 (27 worldwide citation)

The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.


19
Claremon David A: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. VITAE PHARMACEUTICALS, Davis Steven G, August 12, 2010: WO/2010/091067 (27 worldwide citation)

This invention relates to novel compounds of an 11 β-HSD1 inhibitor disclosed herein, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11/3-HSD1 in mammals. T ...


20
DAS SANJOY KUMAR: Analogues for the treatment or prevention of flavivirus infections. VERTEX PHARMACEUTICALS INCORPORATED, Davis Steven G, September 29, 2011: WO/2011/119853 (27 worldwide citation)

Compounds represented by formula I as described herein or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4, R4', R5, R5', m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.